MAIA Biotechnology $33 Million Capital Raise to Fully Fund Pivotal Phase 3 NSCLC Trial

On April 8, 2026, MAIA Biotechnology, Inc. announced that its recent $33 million public offering of common stock, completed in March 2026, is expected to fully fund its ongoing pivotal Phase 3 clinical trial (THIO-104) for ateganosine through completion. Ateganosine is a first-in-class telomere-targeting agent being evaluated as a third-line treatment for non-small cell lung cancer (NSCLC) in combination with a checkpoint inhibitor. The THIO-104 trial is a global, randomized study comparing ateganosine to chemotherapy in approximately 300 patients, with median Overall Survival (OS) as the primary endpoint. The company reported that statistical assessments suggest a high probability of technical success if Phase 3 results align with earlier Phase 2 data. Furthermore, MAIA expects to report interim data from the Phase 3 trial next year, which could potentially support a discussion with the FDA for early full commercial approval in the third-line NSCLC setting. Ateganosine has previously received FDA Fast Track designation for this indication.